Lucia Musacchio, Margherita Turinetto, Laura Arenare, Michele Bartoletti, Daniela Califano, Valentina Tuninetti, Claudia Marchetti, Gennaro Cormio, Vera Loizzi, Carmela Pisano, Vanda Salutari, Giorgio Valabrega, Domenico Priolo, Sabrina Chiara Cecere, Jole Ventriglia, Francesco Raspagliesi, Francesco Perrone, Anna Fagotti, Domenica Lorusso, Giovanni Scambia, Sandro Pignata
OBJECTIVE: The aim of the present analysis was to explore the efficacy of Bevacizumab (Bev) on survival outcome in advanced low grade serous ovarian cancer (LGSOC) both in first line and in recurrent setting. METHODS: In retrospective observational multicenter study, we described the outcome of LGSOC patients enrolled in the MITO 22 study and treated with chemotherapy (CT) with or without Bev. Patients receiving Bev in first-line or in recurrence were considered and compared with patients receiving CT alone (stage III and IV in first line; platinum based-CT in second line)...
March 23, 2023: Gynecologic Oncology
Blair McNamara, Justin Harold, Diego Manavella, Stefania Bellone, Levent Mutlu, Tobias Max Philipp Hartwich, Margherita Zipponi, Yang Yang-Hartwich, Cem Demirkiran, Miguel Skyler Z Verzosa, Kevin Yang, Jungmin Choi, Weilai Dong, Natalia Buza, Pei Hui, Gary Altwerger, Gloria S Huang, Vaagn Andikyan, Mitchell Clark, Elena Ratner, Masoud Azodi, Peter E Schwartz, Elizabeth A Burton, Hiroaki Inagaki, Aaron Albers, Chao Zhang, Gideon Bollag, Joseph Schlessinger, Alessandro D Santin
INTRODUCTION: Uterine leiomyosarcomas (uLMS) are rare, highly aggressive tumors. Up to 30% of uLMS may harbor gain of function (GOF) in the MAP2K4 gene, important for tumor cell proliferation, differentiation and metastasis. We investigated the in vivo activity of a novel MAP2K4 inhibitor, PLX8725, against uLMS harboring MAP2K4 gene-amplification. METHODS: Two fully characterized uLMS (i.e., LEY-11 and LEY-16) were grafted into female CB-17/SCID mice. Treatments with control vehicle or PLX8725 (50 mg/kg) were given via oral gavage daily on weekdays for up to 60 days...
March 21, 2023: Gynecologic Oncology
Amir Momeni-Boroujeni, Chad Vanderbilt, Elham Yousefi, Nadeem R Abu-Rustum, Carol Aghajanian, Robert A Soslow, Lora H Ellenson, Britta Weigelt, Rajmohan Murali
OBJECTIVE: Chromatin remodeling genes (CRGs) encode components of epigenetic regulatory mechanisms and alterations in these genes have been identified in several tumor types, including gynecologic cancers. In this study, we sought to investigate the prevalence and clinicopathological associations of CRG alterations in endometrial carcinoma (EC). METHODS: We performed a retrospective analysis of 660 ECs sequenced using a clinical massively parallel sequencing assay targeting up to 468 genes, including 25 CRGs, and defined the presence of somatic CRG alterations...
March 20, 2023: Gynecologic Oncology
B Hapuarachi, J A Tidy, C Romanowski, K Singh, S Gillett, J Ireson, M C Winter
OBJECTIVES: Gestational Trophoblastic Neoplasia (GTN) is a rare group of malignant placental-related tumours requiring systemic anti-cancer treatment. Leptomeningeal disease (LMD) related to GTN is not well reported with no consensus in optimal treatment. We offer recommendations for management of these patients. METHODS: We discuss five patients with GTN who presented with features of LMD and were diagnosed with gadolinium-enhanced MRI brain, all of whom received low dose induction etoposide-cisplatin (EP) followed by either EP-etoposide, methotrexate (CNS) and actinomycin-D (EMA) or EMA(CNS)-cyclophosphamide and vincristine (CO)...
March 17, 2023: Gynecologic Oncology
Allison E Grubbs, Nikita Sinha, Ravi Garg, Emma L Barber
STUDY OBJECTIVE: There is scant research identifying thematic trends within medical research. This work may provide insight into how a given field values certain topics. We assessed the feasibility of using a machine learning approach to determine the most common research themes published in Gynecologic Oncology over a thirty-year period and to subsequently evaluate how interest in these topics changed over time. METHODS: We retrieved the abstracts of all original research published in Gynecologic Oncology from 1990 to 2020 using PubMed...
March 16, 2023: Gynecologic Oncology
Alli M Straubhar, Qin Zhou, Alexia Iasonos, Daniel L Clarke-Pearson, William A Cliby, Mitchel S Hoffman, Dennis S Chi
OBJECTIVE: We sought to document current surgical practices among gynecologic oncologists in the United States. METHODS: In March/April 2020, we conducted a cross-sectional survey among members of the Society of Gynecologic Oncology to identify gynecologic oncology practice trends in the United States. The survey collected demographic data and queried participants on types of surgical procedures performed and chemotherapy use. Univariant and multivariant analyses were used to evaluate the association between surgeon practice type, region of practice, working with gynecologic oncology fellows, time in practice, and dominant surgical modality of practice on performance of specific procedures...
March 16, 2023: Gynecologic Oncology
Ann Oluloro, Sarah M Temkin, Jonathan Jackson, Elizabeth M Swisher, Liz Sage, Kemi Doll
OBJECTIVE: Underrepresented groups may be dissuaded from clinical trial participation without perceived value. We therefore comprehensively assessed gynecologic cancer clinical trial protocols for the inclusion of items of value most important to Black individuals. METHODS: was queried for NCI-sponsored gynecologic cancer clinical trials in the US between Jan.1994 and Nov.2021. Pre-specified return of value (ROV) items were abstracted from each protocol...
March 15, 2023: Gynecologic Oncology
Zhishuo Wei, Diego D Luy, Lilly W Tang, Hansen Deng, Shalini Jose, Sydney Scanlon, Ajay Niranjan, L Dade Lunsford
OBJECTIVE: This study aims to evaluate the efficacy of stereotactic radiosurgery (SRS) in improving health outcomes of patients with gynecologic brain metastases. METHODS: Patients with gynecologic metastases treated with SRS from 2008 to 2020 were retrospectively reviewed. The median age at SRS was 63 years old (cervical 45.5, endometrial 65.5, ovarian 61). The median number of tumors was 3 (range 1-27), and cumulative tumor volume was 2.33 cc (range 0...
March 14, 2023: Gynecologic Oncology
Kathryn Osann, Lari Wenzel, Chelsea McKinney, Lynne Wagner, David Cella, Giulia Fulci, Mary J Scroggins, Heather A Lankes, Victoria Wang, Kenneth P Nephew, George L Maxwell, Samuel C Mok, Thomas P Conrads, Austin Miller, Michael Birrer
OBJECTIVE: Although advanced stage epithelial ovarian cancer is widely considered life-threatening, 17% of women with advanced disease will survive long-term. Little is known about the health-related quality of life (QOL) of long-term ovarian cancer survivors, or how fear of recurrence might affect QOL. METHODS: 58 long-term survivors with advanced disease participated in the study. Participants completed standardized questionnaires to capture cancer history, QOL, and fear of recurrent disease (FOR)...
March 9, 2023: Gynecologic Oncology
Elisabeth Spénard, William Geerts, Yulia Lin, Lilian T Gien, Rachel Kupets, Al Covens, Danielle Vicus
INTRODUCTION: Venous thromboembolic events represent the second most frequent cause of mortality in cancer patients. Recent literature shows that direct oral anticoagulants (DOAC) are at least as effective and safe as low molecular weight heparin for postoperative thromboprophylaxis. However, this practice has not been broadly adopted in gynecologic oncology. The aim of this study was to evaluate clinical effectiveness and safety of apixaban for extended thromboprophylaxis in comparison to enoxaparin after laparotomies for gynecologic oncology patients...
March 9, 2023: Gynecologic Oncology
Céline Lechartier, Juliette Bernard, Marie-Claude Renaud, Marie Plante
OBJECTIVE: Obesity has risen to affect >25% of the Canadian population. Perioperative challenges with increased morbidity are encountered. We evaluated the outcome of robotic-assisted surgery for endometrial cancer (EC) in obese patients. METHODS: We retrospectively reviewed all robotic surgeries performed for EC in women with BMI ≥40 kg/m2, from 2012 to 2020 in our center. Patients were divided into 2 groups (class III: 40-49 kg/m2, class IV: ≥50 kg/m2)...
March 9, 2023: Gynecologic Oncology
Anne Høy Seemann Vestergaard, Mette Asbjoern Neergaard, Lars Ulrik Fokdal, Christian Fynbo Christiansen, Jan Brink Valentin, Søren Paaske Johnsen
OBJECTIVE: To examine hospital-based specialist palliative care (SPC) utilisation among patients with gynaecological cancer, including temporal trends, predictors and associations with high-intensity end-of-life care. METHODS: We conducted a nationwide registry-based study for all patients dying from gynaecological cancer in Denmark during 2010-2016. We estimated the proportions of patients receiving SPC by year of death and used regression analyses to examine predictors of SPC utilisation...
March 9, 2023: Gynecologic Oncology
Krishnansu S Tewari, Michael W Sill, Michael J Birrer, Richard T Penson, Helen Huang, David H Moore, Lois M Ramondetta, Lisa M Landrum, Ana Oaknin, Thomas J Reid, Mario M Leitao, Helen E Michael, Bradley J Monk
OBJECTIVE: To determine whether a non‑platinum chemotherapy doublet improves overall survival (OS) among patients with recurrent/metastatic cervical carcinoma. METHODS: Gynecologic Oncology Group protocol 240 is a phase 3, randomized, open-label, clinical trial that studied the efficacy of paclitaxel 175 mg/m2 plus topotecan 0.75 mg/m2 days 1-3 (n = 223) vs cisplatin 50 mg/m2 plus paclitaxel 135 or 175 mg/m2 (n = 229), in 452 patients with recurrent/metastatic cervical cancer...
March 8, 2023: Gynecologic Oncology
Megan P Hitchins, Rocio Alvarez, Lisa Zhou, Francesca Aguirre, Estela Dámaso, Marta Pineda, Gabriel Capella, Justin J-L Wong, Xiaopu Yuan, Shawnia R Ryan, Devika S Sathe, Melanie D Baxter, Timothy Cannon, Rakesh Biswas, Tiffani DeMarco, Doreen Grzelak, Heather Hampel, Rachel Pearlman
OBJECTIVE: Universal screening of endometrial carcinoma (EC) for mismatch repair deficiency (MMRd) and Lynch syndrome uses presence of MLH1 methylation to omit common sporadic cases from follow-up germline testing. However, this overlooks rare cases with high-risk constitutional MLH1 methylation (epimutation), a poorly-recognized mechanism that predisposes to Lynch-type cancers with MLH1 methylation. We aimed to determine the role and frequency of constitutional MLH1 methylation among EC cases with MMRd, MLH1-methylated tumors...
March 7, 2023: Gynecologic Oncology
Sarah Marie Bjørnholt, Sarah Elizabeth Sponholtz, Ole Mogensen, Kirsten Bouchelouche, Erik Thorlund Parner, Gudrun Neumann, Kirsten Marie Jochumsen, Bushra Hassan Hamid, Morten Bülow Davidsen, Signe Frahm Bjørn, Katja Dahl, Pernille Tine Jensen
OBJECTIVE: The SENTIREC-endo study aims to investigate risks and benefits of a national protocolled adoption of sentinel lymph node (SLN) mapping in women with early-stage low-grade endometrial cancer (EC) with low- (LR) and intermediate-risk (IR) of lymph node metastases. METHODS: We performed a national multicenter prospective study of SLN-mapping in women with LR and IR EC from March 2017-February 2022. Postoperative complications were classified according to Clavien-Dindo...
March 7, 2023: Gynecologic Oncology
L R Moolenaar, L E van Rangelrooij, M I E van Poelgeest, M van Beurden, W J van Driel, L R C W van Lonkhuijzen, C H Mom, A Zaal
OBJECTIVES: The aim of this study was to analyze morbidity and survival after pelvic exenteration for gynecologic malignancies and evaluate prognostic factors influencing postoperative outcome. METHODS: We retrospectively reviewed all patients who underwent a pelvic exenteration at the departments of gynecologic oncology of three tertiary care centers in the Netherlands, the Leiden University Medical Centre, the Amsterdam University Medical Centre, and the Netherlands Cancer Institute, during a 20-year period...
March 2, 2023: Gynecologic Oncology
Félix Blanc-Durand, Elisa Yaniz-Galende, Alba Llop-Guevara, Catherine Genestie, Violeta Serra, Andrea Herencia-Ropero, Christophe Klein, Dominique Berton, Alain Lortholary, Nadine Dohollou, Christophe Desauw, Michel Fabbro, Emmanuelle Malaurie, Nathalie Bonichon-Lamaichhane, Coraline Dubot, Jean Emmanuel Kurtz, Gaëtan de Rauglaudre, Nadia Raban, Annick Chevalier-Place, Gwenael Ferron, Marie-Christine Kaminsky, Claire Kramer, Etienne Rouleau, Alexandra Leary
RATIONALE: Homologous recombination deficiency (HRD), defined as BRCA1/2 mutation (BRCAmut) or high genomic instability, is used to identify ovarian cancer (OC) patients most likely to benefit from PARP inhibitors. While these tests are useful, they are imperfect. Another approach is to measure the capacity of tumor cells to form RAD51 foci in the presence of DNA damage using an immunofluorescence assay (IF). We aimed to describe for the first time this assay in OC and correlate it to platinum response and BRCAmut...
March 1, 2023: Gynecologic Oncology
Angiolo Gadducci, Francesco Multinu, Luigi Antonio De Vitis, Stefania Cosio, Silvestro Carinelli, Giovanni Damiano Aletti
Endometrial stromal tumors (EST) are uterine mesenchymal tumors, which histologically resemble endometrial stroma of the functioning endometrium. The majority of EST are malignant tumors classified as low-grade endometrial stromal sarcoma (LG-ESS), high-grade endometrial stromal sarcoma (HG-ESS), and undifferentiated uterine sarcoma (UUS). Overall, ESTs are rare malignancies, with an annual incidence of approximately 0.30 per 100'000 women, mainly affecting peri- or postmenopausal women. The most common genetic alteration identified in LG-ESS is the JAZF1-SUZ12 rearrangement, while t(10;17)(q23,p13) translocation and BCOR gene abnormalities characterize two major subtypes of HG-ESS...
February 24, 2023: Gynecologic Oncology
C S E Hendrikse, P M M Theelen, P van der Ploeg, H M Westgeest, I A Boere, A M J Thijs, P B Ottevanger, A van de Stolpe, S Lambrechts, R L M Bekkers, J M J Piek
BACKGROUND: The RAS/RAF/MEK/ERK (MAPK) pathway plays a role in ovarian carcinogenesis. Low-grade serous ovarian carcinoma (LGSOC) frequently harbors activating MAPK mutations. MAPK inhibitors have been used in small subsets of ovarian carcinoma (OC) patients to control tumor growth. Therefore, we performed a meta-analysis to evaluate the effectiveness of MAPK inhibitors in OC patients. We aimed to determine the clinical benefit rate (CBR), the subgroup of MAPK inhibitors with the best CBR and overall response rate (ORR), and the most common adverse events...
February 23, 2023: Gynecologic Oncology
Stephanie V Blank, Warner K Huh, Maria Bell, Sarah Dilley, Melissa Hardesty, Ebony R Hoskins, Jason Lachance, Fernanda Musa, Emily Prendergast, B J Rimel, Mark Shahin, Fidel Valea
The original vision of the field of gynecologic oncology was to establish a multidisciplinary approach to the management of patients with gynecologic cancers. Fifty years later, scientific advances have markedly changed the overall practice of gynecologic oncology, but the profession continues to struggle to define its value-financial and otherwise. These issues were examined in full at the Society of Gynecologic Oncology (SGO) Future of the Profession Summit and the purpose of this document is to summarize the discussion, share the group's perceived strengths, weaknesses, opportunities, and threats (SWOT) for gynecologic oncologists, further educate members and others within the patient care team about the unique role of gynecologic oncologists, and plan future steps in the short- and long- term to preserve the subspecialty's critical mission of providing comprehensive, longitudinal care for people with gynecologic cancers...
February 22, 2023: Gynecologic Oncology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.